EEF1B2P5: A Potential Drug Target and Biomarker (G442227)

Target Name: EEF1B2P5

NCBI ID: G442227

EEF1B2P5

Other Name(s): eukaryotic translation elongation factor 1 beta 2 pseudogene 5 | Eukaryotic translation elongation factor 1 beta 2 pseudogene 5

EEF1B2P5: A Potential Drug Target and Biomarker

The eukaryotic translation elongation factor 1 (EF1) beta 2 pseudogene 5 (EEF1B2P5) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. Discovered in 2016, EEF1B2P5 has been shown to promote the translation of its own gene and other genes, making it a potential drug target and biomarker.

The EEF1B2P5 gene is located on chromosome 16q24 and has 21 base pairs of DNA. It is a part of theef1 gene family, which is known to be involved in the regulation of gene expression and translation in eukaryotic cells. The EEF1 gene is a key regulator of gene expression in many organisms, including humans.

EEF1B2P5 functions as a negative regulator of the translation of its own gene and other genes. It does this by interacting with the RNA polymerase II (RNA-pol) complex, which is responsible for translating DNA into RNA. By interacting with RNA-pol, EEF1B2P5 prevents the RNA-pol complex from using the EEF1B2P5 gene as a target for translation.

This mechanism of action is important because it allows the EEF1B2P5 gene to be translated into RNA and studied experimentally. Researchers have used RNA-seq techniques to identify EEF1B2P5 RNA levels in various tissues and cells, including brain, heart, and cancer. These studies have provided valuable insights into the regulation of gene expression in eukaryotic cells.

In addition to its role as a negative regulator of translation, EEF1B2P5 has also been shown to be a potential drug target. The ability of EEF1B2P5 to promote the translation of its own gene and other genes makes it a potential target for small molecules that can inhibit its function. This has led to a number of patents and research articles exploring the potential of small molecules as drugs for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

EEF1B2P5 has also been shown to be a potential biomarker for several diseases, including cancer. The ability of EEF1B2P5 to promote the translation of its own gene and other genes makes it a potential target for cancer therapies that target the regulation of gene expression. This has led to the use of EEF1B2P5 as a biomarker for cancer diagnosis and treatment.

In conclusion, EEF1B2P5 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. Its function as a negative regulator of translation and its potential as a drug target and biomarker make it an attractive target for small molecules and therapies for a variety of diseases. Further research is needed to fully understand the role of EEF1B2P5 in eukaryotic cells and its potential as a drug.

Protein Name: Eukaryotic Translation Elongation Factor 1 Beta 2 Pseudogene 5

The "EEF1B2P5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1B2P5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets